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Recently, a five-center collaborative study1 reported that ge-netic variations of glypican-5 (GPC5) may significantly
contribute to an increased risk of lung cancer in never smokers.
GPC5 gene expression levels in normal lung tissues were found
significantly lower in individuals who carry high-risk alleles,
and the GPC5 expression level in adenocarcinoma tissue was
significantly lower than in matched normal lung tissue. Reduc-
tion of expression of GPC5 may lead to the development of lung
cancer, suggesting that this gene normally functions as a tumor
suppressor.
GPC5 is a member of the glypican gene family. Glypi-
cans are a family of heparan sulfate proteoglycans (HSPGs)
that are linked to the exocytoplasmic surface of the plasma
membrane by a glycosylphosphatidylinositol anchor. There
are six glypican family members in the human genome
(GPC1 to GPC6).2 GPC1 is overexpressed in human pancre-
atic3 and breast cancers.4 GPC3, the family member that
shows highest homology to GPC5, is overexpressed in neu-
roblastoma, Wilm’s tumors,5 and melanoma.6 GPC3 was also
shown to be overexpressed in hepatocellular carcinoma,7 and
engineered GPC3 overexpression in hepatocellular carci-
noma cell lines was associated with modulated proliferation.8
Missense mutations in GPC3 are found in Simpson-Golabi-
Behmel syndrome, which is associated with overgrowth and
a reported predisposition to develop pediatric tumors.9
GPC5 gene has eight exons encoding 572 amino acids
and spans a large genomic region of 1.47 Mb at chromosome
13q31.3.10 Alterations at the GPC5 locus are a common event
in various human tumors. Amplifications at 13q31-32 are
frequently seen across several tumor types, including lym-
phomas, breast cancers, and neurologic tumors.11–13 For lung
cancer, an array comparative genomic hybridization (CGH)-
based study reported a homozygous deletion at 13q31.3 in a
non-small cell lung cancer cell line.14 Another array CGH-
based study recently analyzed a series of 14 patients with 13q
partial deletion syndrome and noted lung hypoplasia as one of
the common phenotypes. Among the 14 patients, two had
lung hypoplasia.15 Amplification and overexpression of the
miR-17-92 miRNA cluster at 13q31.3 was recently reported
in lung cancers from one study16; another study showed that
inhibition of miR-17-5p and miR-20a with antisense oligo-
nucleotides can induce apoptosis selectively in lung cancer
cells overexpressing miR-17-92.17 When using TargetScan
(http://www.targetscan.org/vert_50/) to predict biologic tar-
gets of miRNAs, miR-17, miR-20a, miR-20b, miR-23a, and
miR-23b were found to target GPC5 3 untranslated region.
These results suggested that miRNA regulating GPC5 ex-
pression may be important in the development of lung can-
cers and warrant in-depth investigation. Moreover, epigenetic
silencing by hypermethylation of the CpG-rich region of
GPC5 leads to loss of GPC5 function, which may in turn lead
to carcinogenesis. Additional studies will be required to
unravel the mechanisms of silencing or mutations of 13q31.3
region and its role in lung cancer.
Different single-nucleotide polymorphisms in GPC5
have also been implicated in susceptibility to multiple scle-
rosis (MS).18 A recent meta-analysis of cancer risk in MS has
shown that the risk of lung cancer is significantly decreased
in individuals with MS.19 One study showed a particularly
strongly decreased risk for cancers of the respiratory tract in
MS patients.20 HSPGs were found to be often expressed in
reduced amounts in non-small cell lung carcinomas, particu-
larly poorly differentiated tumors, compared with normal
epithelia.21 Our results also showed that GPC5 expression is
significantly lower in adenocarcinoma than in matched nor-
mal lung tissue.1 In the ONCOMINE microarray databases,
there are nine studies on lung cancer,22–30 seven22–28 of which
included lung adenocarcinoma. Two datasets25,28 showed
significant downregulation of GPC5 in adenocarcinoma tu-
mors compared with normal lung tissue. Importantly, two
studies25,26 included smoking status information, and both
showed lower expression in never smokers than in smokers.
Four studies23,24,29,30 reported the GPC5 expression informa-
tion from other histologic types, including carcinoid, squa-
mous, small-cell carcinoma, and large-cell carcinoma, and
showed no significant differences in GPC5 expression be-
tween tumor and normal tissues. Thus, reduced GPC5 ex-
pression could be specific to adenocarcinoma in never smok-
ers. However, owing to sample sizes and the different
characteristics of study samples available in ONCOMINE,
this conclusion needs to be further validated. All the current
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evidence seems to support GPC5 to be a protective factor
from developing lung cancer; mechanisms are open for fur-
ther investigation.
Although there is no direct evident for GPC5, HSPGs
as a group are known to interact with many proteins
including growth factors, chemokines, and structural pro-
teins of the extracellular matrix to influence cell growth,
differentiation, and the cellular response to the environ-
ment.31 The main function of the membrane-attached
glypicans is to regulate the signaling pathways of Wnt,
hedgehog (Hh), and fibroblast growth factors (FGF).32 A
recent study has shown that GPC5 increases proliferation
in rhabdomyosarcoma through potentiating the effects of
FGF2 and Wnt1; GPC5 enhanced the intracellular signal-
ing of FGF2 and altered the cellular distribution of
FGF2.33 Previous and recent studies have highlighted po-
tentially significant roles for Wnt, Hh, and FGF signaling
pathways in lung cancer development.
Dysregulated Wnt signaling has been found in lung can-
cer, in particular, non-small cell lung cancer (NSCLC).34,35
FIGURE 1. Possible signal network of GPC5 in lung cancer development. The main function of membrane-attached GPC5 is
thought to regulate the pathway signaling of Wnt, Hedgehogs (Hh), and fibroblast growth factors (FGFs). Depending on the bio-
logic context, GPC5 can either stimulate or inhibit cell signaling activity. GPC5 may bind to Wnt and to the Frizzled receptor in as-
sociation with the coreceptors LRP5/6. Activation of the Frizzled receptor results in subsequent activation of Dishevelled. Through an
unknown mechanism, Dishevelled inhibits the function of a multiprotein complex including Axin, APC, CK-, and GSK-, which
blocks phosphorylation of -catenin and prevents its degradation. Increasing levels of free -catenin translocate to the nucleus,
complex with the TCF/LEF cofactors, and activate target genes. In the case of the Hh pathway, it is proposed that GPC5 may in-
hibit the signaling by competing with Patched (the Hh receptor) for Hh binding. Binding Hh with the Patched receptor alters the
interaction of Patched with Smoothened, a G protein-coupled receptor, resulting in the activation of Smoothened. This initiates a
cascade of events resulting in the Gli entering the nucleus and acting as transcriptional activators. When the Hh signaling is lacking,
Gli is bound to a multiprotein complex consisting of Fu and SuFu and will not enter the nucleus. GPC5 may activate the FGF path-
way through unknown mechanisms. After FGF ligand binding and receptor dimerization, the kinase domains transphosphorylate
each other, leading to the docking of adaptor proteins and the activation of four key downstream pathways: RAS-RAF-MAPK, PI3K-
AKT, STAT, and PLC. The biologic outcomes of FGF/FGFR activation are dependent on a complex network of signaling and tran-
scriptional events regulated by multiple factors. CK-, casein kinase ; GSK-, glycogen synthase kinase ; APC, adenomatous pol-
yposis coli; TCF, T cell-specific transcription factor; LEF, lymphoid enhancer-binding factor; Hh, hedgehog; Fu, fused; SuFu,
suppressor of Fu; GPI, glycosylphosphatidylinositol; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; FRS2,
FGFR substrate 2; GRB2, growth factor receptor-bound 2; Sos, son of sevenless; PLC, phospholipase C ; STAT, signal-transducer
and activator of transcription protein; MAPK, mitogen-activated kinase-like protein.
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Several Wnt proteins are differentially expressed in NSCLC
specimens, including Wnt1, -2, and -7a. Wnt1 and Wnt2 are
overexpressed in NSCLC samples, and cancer cells expressing
Wnt1 are resistant to apoptotic therapies.36,37 Conversely, inhi-
bition of Wnt1 and Wnt2 led to apoptosis in human cancer cells
and reduced tumor growth in vivo and in vitro.36,38 Wnt7a is
decreased in NSCLC; its re-expression leads to growth inhibi-
tion of NSCLC cell lines.39
Persistent Hh pathway activation is seen in small cell
lung cancer (SCLC), which is manifested by a high level of
expression of sonic hedgehog (Shh), Patched, and GLi1.40
Treatment of SCLC cell lines with a specific inhibitor of the
Hh pathway (cyclopamine) produced tumor growth arrest.
Cell lines were protected from cyclopamine inhibition by
constitutive overexpression of the Hh pathway transcription
factor GLi1.41 Studies on cell lines demonstrated that five of
seven SCLC cell lines expressed both Shh and Gli1 in
contrast to NSCLC, which expressed only Shh but not Gli1.
Analysis of clinical samples of human lung cancer tissue
demonstrated 50% (5 of 10) of SCLC expressed both Shh and
Gli1 compared with only 10% (4 of 40) of NSCLC.42 Another
study reported that 85% (34 of 40) of SCLC expressed Gli1
and more than 60% have a medium to strong expression
correlating with increased Hh signaling.43 Thus, it seems that
the degree of dependence on Hh signaling varies among the
subtypes of lung cancer.
Fibroblast growth factor (FGF) belongs to a family of
ubiquitously expressed ligands, which bind to the extracellu-
lar domain of fibroblast growth factor receptors (FGFRs),
initiating a signal transduction cascade, which promotes cell
proliferation, motility, and angiogenesis. Dysregulation of the
FGF signaling pathway has been associated with cancer
development.44–46 The FGF pathway has been shown to be
activated in lung cancer.47–51 Elevated levels of FGF and
FGFR proteins have been detected in NSCLC cell lines and
in human lung cancers.49,52,53 Behrens et al.54 described high
levels of immunohistochemical expression of basic FGF,
FGFR1, and FGFR2 in a large series of NSCLC specimens,
including the two most frequent histologic types, squamous
cell carcinoma and adenocarcinoma. Behrens et al. found
higher levels of basic FGF and FGFRs expression in tumor
cells than in adjacent normal bronchial epithelia at cytoplas-
mic localization in both squamous cell carcinoma and ade-
nocarcinoma. In addition, in adenocarcinoma specimens, Be-
hrens et al. detected differences in the expression of the three
markers and patients’ smoking status, with cytoplasmic
FGFR1 expression being significantly higher in smokers and
nuclear FGFR1 and FGFR2 significantly higher in never
smokers. These differences highlight the potential differential
role of these proteins in the pathogenesis of both smoking and
nonsmoking-related lung cancers. Another recent study sup-
ports the previous studies and also provides molecular evi-
dence for an active FGF autocrine signaling pathway in a
subset of NSCLC cell lines.55
In summary, with all the information of GPC5 and the
glypican family, we hypothesize that GPC5 regulates lung
cancer development through a complex pathway network,
particularly through Wnt, Hh, and FGF signaling pathways
and their interactions. As shown in Figure 1, depending on
the context, GPC5 may have a stimulatory or inhibitory
activity on these pathways, which are important in regulating
cell proliferation, division, and survival. The challenge in the
future will be to elucidate the precise regulation mechanisms
of the GPC5 signaling pathway in lung tumorigenesis and in
lung cancer of never smokers and smokers. A better under-
standing of GPC5’s role in signaling pathways, particularly
the upstream event that suppresses GPC5 expression and
reduces functional GPC5, or the downstream event that
unleashes the oncogenic processes may provide a unique
opportunity for developing novel and effective strategies for
early detection, targeted chemoprevention, and treatment of
lung cancer.
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